Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003498937 | SCV004262529 | uncertain significance | Emery-Dreifuss muscular dystrophy 5, autosomal dominant | 2024-01-11 | criteria provided, single submitter | clinical testing | This sequence change replaces phenylalanine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 4019 of the SYNE2 protein (p.Phe4019Leu). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SYNE2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The leucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV004369000 | SCV004958862 | uncertain significance | not specified | 2023-09-22 | criteria provided, single submitter | clinical testing | The c.12057C>A (p.F4019L) alteration is located in exon 61 (coding exon 60) of the SYNE2 gene. This alteration results from a C to A substitution at nucleotide position 12057, causing the phenylalanine (F) at amino acid position 4019 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |